AIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel

Trial Profile

AIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2018

At a glance

  • Drugs Eftilagimod alpha (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AIPAC
  • Sponsors Immutep
  • Most Recent Events

    • 29 Mar 2018 According to a Prima BioMed media release, this study is expected to be fully recruited in in mid-2018 and report top-line progression free survival data by mid-2019.
    • 28 Nov 2017 According to a Prima BioMed media release, Prima BioMed changed its name to Immutep Limited.
    • 31 Oct 2017 According to a Prima BioMed media release, immune monitoring data from the study has been presented at World Immunotherapy Congress 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top